Literature DB >> 3284691

Pharmacokinetics of high-dose etoposide.

E M Newman1, J H Doroshow, S J Forman, K G Blume.   

Abstract

The pharmacokinetics of etoposide at doses of 1 gm/m2 to 3 gm/m2 were studied in patients with hematologic malignancies. The noncompartmental systemic clearance, mean residence time, steady-state volume of distribution, and elimination half-life were independent of the dose of etoposide, whereas the AUC was proportional to the dose. Comparison of these results with those reported previously indicates that etoposide exhibits linear pharmacokinetics over a thirtyfold range in doses (0.1 to 3 gm/m2).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3284691     DOI: 10.1038/clpt.1988.73

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution.

Authors:  G Ehninger; B Proksch; H Schmidt; P Waidelich; B Eichel; R Dopfer
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Early disturbance of microvascular function precedes chemotherapy-induced intestinal injury.

Authors:  E Abel; T Ekman; E Warnhammar; R Hultborn; E Jennische; S Lange
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

4.  Disposition of total and unbound etoposide following high-dose therapy.

Authors:  T L Schwinghammer; R A Fleming; C S Rosenfeld; D Przepiorka; R K Shadduck; E J Bloom; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Pharmacokinetics of high-dose etoposide after short-term infusion.

Authors:  P Köhl; H Köppler; L Schmidt; H W Fritsch; J Holz; K H Pflüger; H Jungclas
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Multiple-pool cell lifespan model of hematologic effects of anticancer agents.

Authors:  Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

7.  Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma.

Authors:  J A Sparano; P H Wiernik; X Hu; C Sarta; D H Henry; H Ratech
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

8.  Instability of the anticancer agent etoposide under in vitro culture conditions.

Authors:  R M Mader; G G Steger; K Moser; H Rainer; P Krenmayr; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.